Log in
NASDAQ:OFIX

Orthofix Medical Competitors

$37.14
+0.99 (+2.74 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.38
Now: $37.14
$37.62
50-Day Range
$31.26
MA: $34.42
$38.26
52-Week Range
$22.11
Now: $37.14
$47.91
Volume80,461 shs
Average Volume134,593 shs
Market Capitalization$718.06 million
P/E Ratio30.95
Dividend YieldN/A
Beta1.01

Competitors

Orthofix Medical (NASDAQ:OFIX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying OFIX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Orthofix Medical, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Orthofix Medical (NASDAQ:OFIX) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Earnings & Valuation

This table compares Orthofix Medical and Abbott Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orthofix Medical$459.95 million1.56$-28,460,000.00$1.4725.27
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Orthofix Medical and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Orthofix Medical02102.33
Abbott Laboratories141302.67

Orthofix Medical presently has a consensus target price of $45.6667, suggesting a potential upside of 22.96%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given Orthofix Medical's higher probable upside, equities analysts clearly believe Orthofix Medical is more favorable than Abbott Laboratories.

Volatility and Risk

Orthofix Medical has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Profitability

This table compares Orthofix Medical and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Orthofix Medical-5.22%2.47%1.60%
Abbott Laboratories10.50%18.19%8.29%

Institutional & Insider Ownership

93.8% of Orthofix Medical shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 3.5% of Orthofix Medical shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Abbott Laboratories beats Orthofix Medical on 10 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Orthofix Medical (NASDAQ:OFIX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Medtronic and Orthofix Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Orthofix Medical$459.95 million1.56$-28,460,000.00$1.4725.27

Medtronic has higher revenue and earnings than Orthofix Medical. Medtronic is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Medtronic and Orthofix Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Orthofix Medical02102.33

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Orthofix Medical has a consensus price target of $45.6667, suggesting a potential upside of 22.96%. Given Orthofix Medical's higher probable upside, analysts plainly believe Orthofix Medical is more favorable than Medtronic.

Volatility & Risk

Medtronic has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Medtronic and Orthofix Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Orthofix Medical-5.22%2.47%1.60%

Institutional & Insider Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 93.8% of Orthofix Medical shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 3.5% of Orthofix Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Medtronic beats Orthofix Medical on 11 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Orthofix Medical (NASDAQ:OFIX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Stryker and Orthofix Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Orthofix Medical$459.95 million1.56$-28,460,000.00$1.4725.27

Stryker has higher revenue and earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Stryker and Orthofix Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Orthofix Medical02102.33

Stryker presently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Orthofix Medical has a consensus price target of $45.6667, suggesting a potential upside of 22.96%. Given Orthofix Medical's higher probable upside, analysts plainly believe Orthofix Medical is more favorable than Stryker.

Volatility & Risk

Stryker has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Stryker and Orthofix Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Orthofix Medical-5.22%2.47%1.60%

Institutional & Insider Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 93.8% of Orthofix Medical shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 3.5% of Orthofix Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Stryker beats Orthofix Medical on 12 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Orthofix Medical (NASDAQ:OFIX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Earnings and Valuation

This table compares Intuitive Surgical and Orthofix Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
Orthofix Medical$459.95 million1.56$-28,460,000.00$1.4725.27

Intuitive Surgical has higher revenue and earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Intuitive Surgical and Orthofix Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
Orthofix Medical02102.33

Intuitive Surgical presently has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Orthofix Medical has a consensus price target of $45.6667, suggesting a potential upside of 22.96%. Given Orthofix Medical's higher probable upside, analysts plainly believe Orthofix Medical is more favorable than Intuitive Surgical.

Profitability

This table compares Intuitive Surgical and Orthofix Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Orthofix Medical-5.22%2.47%1.60%

Institutional & Insider Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 93.8% of Orthofix Medical shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 3.5% of Orthofix Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Intuitive Surgical beats Orthofix Medical on 10 of the 14 factors compared between the two stocks.

Becton, Dickinson and (NYSE:BDX) and Orthofix Medical (NASDAQ:OFIX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk and Volatility

Becton, Dickinson and has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Earnings & Valuation

This table compares Becton, Dickinson and and Orthofix Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40
Orthofix Medical$459.95 million1.56$-28,460,000.00$1.4725.27

Becton, Dickinson and has higher revenue and earnings than Orthofix Medical. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Becton, Dickinson and and Orthofix Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and07712.60
Orthofix Medical02102.33

Becton, Dickinson and presently has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Orthofix Medical has a consensus price target of $45.6667, suggesting a potential upside of 22.96%. Given Orthofix Medical's higher probable upside, analysts clearly believe Orthofix Medical is more favorable than Becton, Dickinson and.

Profitability

This table compares Becton, Dickinson and and Orthofix Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
Orthofix Medical-5.22%2.47%1.60%

Institutional and Insider Ownership

74.4% of Becton, Dickinson and shares are held by institutional investors. Comparatively, 93.8% of Orthofix Medical shares are held by institutional investors. 0.1% of Becton, Dickinson and shares are held by insiders. Comparatively, 3.5% of Orthofix Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Becton, Dickinson and beats Orthofix Medical on 11 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Orthofix Medical (NASDAQ:OFIX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk and Volatility

Edwards Lifesciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Earnings & Valuation

This table compares Edwards Lifesciences and Orthofix Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54
Orthofix Medical$459.95 million1.56$-28,460,000.00$1.4725.27

Edwards Lifesciences has higher revenue and earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Edwards Lifesciences and Orthofix Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences251302.55
Orthofix Medical02102.33

Edwards Lifesciences presently has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Orthofix Medical has a consensus price target of $45.6667, suggesting a potential upside of 22.96%. Given Orthofix Medical's higher probable upside, analysts clearly believe Orthofix Medical is more favorable than Edwards Lifesciences.

Profitability

This table compares Edwards Lifesciences and Orthofix Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences18.18%29.00%18.10%
Orthofix Medical-5.22%2.47%1.60%

Institutional and Insider Ownership

79.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 93.8% of Orthofix Medical shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 3.5% of Orthofix Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Edwards Lifesciences beats Orthofix Medical on 10 of the 14 factors compared between the two stocks.


Orthofix Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.